Eli Lilly (LLY) Stock Climbs on Positive Arthritis Drug Test Results - TheStreet.com

NEW YORK (TheStreet) -- Shares of Eli Lilly (LLY - Get Report) are up by 0.3% to $79.95 in mid-morning trading on Tuesday, after the company's joint experimental rheumatoid arthritis drug treatment, developed with Incyte (INCY) , was found to be more effective than a current leading treatment.

The treatment Baricitinib showed signs of effectively reducing symptoms of rheumatoid arthritis better than Methotrexate, which has been in use for decades, after 24 weeks.

Read Full Story